Science Explorer Back to mapMap
Discussion
Institution · Colorado Center for Bone Research

Most cited papers from Colorado Center for Bone Research

Colorado Center for Bone Research

What are the most cited papers from Colorado Center for Bone Research?

The most cited paper from Colorado Center for Bone Research is "Effect of Risedronate on the Risk of Hip Fracture in Elderly Women" (Michael R. McClung, Piet Geusens, Paul D. Miller et al., 2001), with 1,931 citations. Next come "Identification and Fracture Outcomes of Undiagnosed Low Bone Mineral Density in Postmenopausal Women" (1,228) and "Denosumab in Postmenopausal Women with Low Bone Mineral Density" (1,225).

Showing 50 of 60 papers. Every paper with more than 145 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Effect of Risedronate on the Risk of Hip Fracture in Elderly Women Michael R. McClung, Piet Geusens, Paul D. Miller et al. · New England Journal of Medicine Open access Feb 2001 1,931
2 Identification and Fracture Outcomes of Undiagnosed Low Bone Mineral Density in Postmenopausal Women Ethel S. Siris, Paul D. Miller, Elizabeth Barrett‐Connor et al. · JAMA 12 Dec 2001 1,228
3 Denosumab in Postmenopausal Women with Low Bone Mineral Density Michael R. McClung, E. Michael Lewiecki, Stanley B. Cohen et al. · New England Journal of Medicine Open access 22 Feb 2006 1,225
4 American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2016--Executive Summary Pauline M. Camacho, Steven M. Petak, Neil Binkley et al. · Endocrine Practice 2016 1,147
5 A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study Charles H. Chesnut, Stuart L. Silverman, Kim Andriano et al. · The American Journal of Medicine Sep 2000 1,129
6 Alendronate for the Treatment of Osteoporosis in Men ERIC S. ORWOLL, Mark P. Ettinger, Stuart R. Weiss et al. · New England Journal of Medicine Open access 31 Aug 2000 977
7 Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis Paul D. Miller, Gary Hattersley, Bente Juel Riis et al. · JAMA Open access 16 Aug 2016 869
8 Interim Report and Recommendations of the World Health Organization Task-Force for Osteoporosis Harry K. Genant et al. · Osteoporosis International Sep 1999 792
9 Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its Use Anthony B. Hodsman, Douglas C. Bauer, David W. Dempster et al. · Endocrine Reviews 15 Mar 2005 724
10 Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass Henry G. Bone, Michael A. Bolognese, Chui Kin Yuen et al. · The Journal of Clinical Endocrinology & Metabolism 3 Feb 2011 629
11 International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions E. Michael Lewiecki, Catherine M. Gordon, Sanford Baim et al. · Bone 16 Aug 2008 582
12 Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial Paul D. Miller, Michael A. Bolognese, E. Michael Lewiecki et al. · Bone 27 Apr 2008 580
13 Osteoporosis and Fracture Risk in Women of Different Ethnic Groups Elizabeth L Barrett-Connor, Ethel S. Siris, Lois E. Wehren et al. · Journal of Bone and Mineral Research Feb 2005 558
14 Changes in Bone Density and Turnover Explain the Reductions in Incidence of Nonvertebral Fractures that Occur during Treatment with Antiresorptive Agents Marc C. Hochberg, Susan L. Greenspan, Richard D. Wasnich et al. · The Journal of Clinical Endocrinology & Metabolism Open access Apr 2002 456
15 Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday Michael R. McClung, Steven T. Harris, Paul D. Miller et al. · The American Journal of Medicine 19 Dec 2012 455
16 Comparison of a Single Infusion of Zoledronic Acid with Risedronate for Paget's Disease Ian R. Reid, Paul D. Miller, Kenneth W. Lyles et al. · New England Journal of Medicine Open access 31 Aug 2005 439
17 Antifracture Efficacy of Antiresorptive Agents Are Related to Changes in Bone Density Richard D. Wasnich, Paul D. Miller · The Journal of Clinical Endocrinology & Metabolism 2000 403
18 Quantitative Ultrasound in the Management of Osteoporosis: The 2007 ISCD Official Positions Marc-Antoine Krieg, Reinhart Barkmann, Stefano Gonnelli et al. · Journal of Clinical Densitometry 2008 385
19 Discordance in Patient Classification Using T-Scores Kenneth G. Faulkner, Eric von Stetten, Paul D. Miller · Journal of Clinical Densitometry Sep 1999 380
20 A Randomized Double-Blind Trial to Compare the Efficacy of Teriparatide [Recombinant Human Parathyroid Hormone (1–34)] with Alendronate in Postmenopausal Women with Osteoporosis Jean‐Jacques Body, Gregory A. Gaich, Wim H. Scheele et al. · The Journal of Clinical Endocrinology & Metabolism Oct 2002 366
21 Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis Felicia Cosman, Erik Fink Eriksen, Chris P. Recknor et al. · Journal of Bone and Mineral Research 2 Sep 2010 361
22 Treatment With Once-Weekly Alendronate 70 mg Compared With Once-Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double-Blind Study Clifford james Rosen, Marc C. Hochberg, Sydney Lou Bonnick et al. · Journal of Bone and Mineral Research Open access 2005 339
23 Prediction of Fracture Risk in Postmenopausal White Women With Peripheral Bone Densitometry: Evidence From the National Osteoporosis Risk Assessment Paul D. Miller, Ethel S. Siris, Elizabeth L Barrett-Connor et al. · Journal of Bone and Mineral Research Dec 2002 337
24 Monthly Oral Ibandronate Therapy in Postmenopausal Osteoporosis: 1-Year Results From the MOBILE Study Paul D. Miller, Michael R. McClung, Liviu Macovei et al. · Journal of Bone and Mineral Research Aug 2005 335
25 A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis E. Michael Lewiecki, Tomasz Blicharski, Stefan Goemaere et al. · The Journal of Clinical Endocrinology & Metabolism Open access 20 Jun 2018 329
26 Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study Reginster Jy, S. Adámi, Peter Laszlo Lakatos et al. · Annals of the Rheumatic Diseases Open access 9 Dec 2005 328
27 Safety and Efficacy of Risedronate in Patients With Age-Related Reduced Renal Function as Estimated by the Cockcroft and Gault Method: A Pooled Analysis of Nine Clinical Trials Paul D. Miller, Christian Roux, Steven Boonen et al. · Journal of Bone and Mineral Research Dec 2005 321
28 Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD E. Michael Lewiecki, Paul D. Miller, Michael R. McClung et al. · Journal of Bone and Mineral Research Open access 20 Aug 2007 321
29 Vertebral Fractures: Clinical Importance and Management David L. Kendler, Douglas C. Bauer, Kenneth Shawn Davison et al. · The American Journal of Medicine 3 Nov 2015 321
30 A Review of the Literature on Osteonecrosis of the Jaw in Patients with Osteoporosis Treated with Oral Bisphosphonates: Prevalence, Risk Factors, and Clinical Characteristics Michael Pazianas, Paul D. Miller, William A. Blumentals et al. · Clinical Therapeutics Aug 2007 300
31 Benefits and Risks of Bisphosphonate Therapy for Osteoporosis Sundeep Khosla, John Paul Bilezikian, David W. Dempster et al. · The Journal of Clinical Endocrinology & Metabolism 20 Apr 2012 289
32 The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50–99: results from the National Osteoporosis Risk Assessment (NORA) Ethel S. Siris, Susan K. Brenneman, Elizabeth L Barrett-Connor et al. · Osteoporosis International 3 Jan 2006 272
33 Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies Ian R. Reid, Paul D. Miller, Jacques P. Brown et al. · Journal of Bone and Mineral Research Open access 8 Jun 2010 253
34 Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates Paul D. Miller, Nicola Pannacciulli, Jacques P. Brown et al. · The Journal of Clinical Endocrinology & Metabolism Open access 6 Jun 2016 240
35 Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment Paul D. Miller, Elliott N. Schwartz, P. Chen et al. · Osteoporosis International 29 Sep 2006 239
36 Effects of Bazedoxifene on BMD and Bone Turnover in Postmenopausal Women: 2-Yr Results of a Randomized, Double-Blind, Placebo-, and Active-Controlled Study Paul D. Miller, Arkadi A. Chines, Claus Christiansen et al. · Journal of Bone and Mineral Research Open access 11 Dec 2007 234
37 A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density ERIC S. ORWOLL et al. · The Journal of Clinical Endocrinology & Metabolism 22 Jun 2012 233
38 Observations following discontinuation of long-term denosumab therapy Michael R. McClung, R.B. Wagman, Paul D. Miller et al. · Osteoporosis International Open access 31 Jan 2017 225
39 Effects of Intravenous Zoledronic Acid Once Yearly on Bone Remodeling and Bone Structure Robert R. Recker, Pierre Dominique Delmas, Johan Halse et al. · Journal of Bone and Mineral Research 24 Sep 2007 225
40 Early Responsiveness of Women with Osteoporosis to Teriparatide After Therapy with Alendronate or Risedronate Paul D. Miller, Pierre Dominique Delmas, Robert Lindsay et al. · The Journal of Clinical Endocrinology & Metabolism Open access 5 Aug 2008 220
41 SOCS2 negatively regulates growth hormone action in vitro and in vivo Christopher J. Greenhalgh, Elizabeth Rico-Bautista, Mattias Lorentzon et al. · Journal of Clinical Investigation Open access Feb 2005 214
42 National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): What They Mean to the Bone Densitometrist and Bone Technologist Nelson B. Watts, E. Michael Lewiecki, Paul D. Miller et al. · Journal of Clinical Densitometry 19 Jun 2008 209
43 ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis Henry G. Bone, Felicia Cosman, Paul D. Miller et al. · The Journal of Clinical Endocrinology & Metabolism Open access 24 May 2018 208
44 Management of severe osteoporosis Paul D. Miller · Expert Opinion on Pharmacotherapy 25 Nov 2015 196
45 A randomized, double-blind comparison of risedronate and etidronate in the treatment of paget’s disease of bone Paul D. Miller, Jacques P. Brown, Ethel S. Siris et al. · The American Journal of Medicine May 1999 192
46 Burosumab for the Treatment of Tumor-Induced Osteomalacia Suzanne M. Jan de Beur, Paul D. Miller, Thomas Joseph Weber et al. · Journal of Bone and Mineral Research Open access Dec 2020 188
47 Osteoclasts are important for bone angiogenesis Frank Cameron Cackowski, Judith L. Anderson, Kenneth D. Patrene et al. · Blood Open access 4 Nov 2009 187
48 Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double-blind, active-controlled study ERIC S. ORWOLL, Paul D. Miller, Jonathan Derrick Adachi et al. · Journal of Bone and Mineral Research Open access 30 Apr 2010 187
49 Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate Michael R. McClung, Robert R. Recker, Paul D. Miller et al. · Bone 25 Mar 2007 177
50 Official positions of the International Society for Clinical Densitometry (ISCD) on DXA evaluation in children and adolescents Maria Luisa Bianchi, Sanford Baim, Nick J. Bishop et al. · Pediatric Nephrology 14 Jul 2009 176

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.